All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Sequencing immune-based therapies in B-cell malignancies
with Ulric Jäger, Sagar Lonial, and Krina Patel
Saturday, June 15 | 18:00-19:30 CEST
Register nowThis independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
Measurable residual disease (MRD), a test used to detect the presence of lymphoma cells after therapy has shown prognostic significance in both B-cell and T-cell acute lymphoblastic leukemia. However, the correlation between end-of-induction (EOI) MRD and clinical outcomes in patients with T-cell lymphoblastic lymphoma (T-LBL) remains unclear.
Here, we summarize a subgroup analysis of the phase III Children’s Oncology Group AALL1231 trial published by Hayashi et al.1 in Blood assessing the correlation between EOI MRD and event-free survival (EFS) in patients with T-LBL.
Figure 1. 4-year EFS and OS rates by MRD*
EFS, event-free survival; MRD, measurable residual disease; OS, overall survival.
*Data from Hayashi, et al.1
Key learnings |
|
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox